Reported in the Open Nutraceuticals Journal of September 2012, this experiment involved a 75-year-old with one of the most irreversible progressive neurodegenerative diseases known: amyotrophic lateral sclerosis (ALS). Also referred to as Lou Gehrig’s disease, ALS affects the skeletal muscular nerve impulses that control contraction and function. It may start with chronic twitching, cramping, and muscular weakness. Then it spreads to total muscular atrophy including the inability to eat, swallow, or breathe, and slurred speech.
A Japanese medical scientist allowed colleagues to do a clinical evaluation of CoQ10 for ALS on him. The 75-year-old scientist had been diagnosed with was treated with a highly bioavailable form of coenzyme Q10 (solubilized ubiquinol) starting at 200 mg, twice daily for 4 weeks (at which point he already experienced improvements), followed by 500 mg, twice daily, and then back down to 200 mg twice daily. His improvements were significant with most of his voluntary motor activity returning along with restoring his grip. The rate of muscular weakening was lowered as well.
Other neurodegenerative studies have shown good signs that CoQ10 may be able to protect and reverse chemically induced brain and nervous system damage by restoring brain and nerve cell metabolism.
|Jarrow Formulas – Q-absorb CoQ10 100 mg. – 120 Softgels|
|Metagenics – Nutra Gems CoQ10 300 mg. – 30 Chewable Gels|
|New Chapter – CoQ10+ Food Complex – 60 Vegetarian Capsules|